Intellia Therapeutics to Present at October Healthcare Investor Conferences
26 September 2022 - 9:30PM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage
genome editing company focused on developing potentially curative
therapeutics leveraging CRISPR-based technologies, today announced
that members of its management team will be presenting at the
following upcoming investor conferences in October:
Chardan’s 6th Annual Genetic Medicines Conference, New
YorkDate: Monday, October 3, 2022Time: 8:30 a.m. ETFormat:
Fireside chat
2022 Truist Securities Genetic Medicine Summit, New
YorkGenome Editing Panel Date: Thursday, October 20,
2022Time: 9:00 a.m. ETFormat: Panel discussion
A live webcast of Intellia’s fireside chat at the Chardan
conference will be accessible through the Events and Presentations
page of the Investors & Media section of the company’s website
at www.intelliatx.com. Replay of the webcast will be available on
Intellia’s website for at least 30 days following the
presentation.
About Intellia TherapeuticsIntellia
Therapeutics, a leading clinical-stage genome editing company, is
developing novel, potentially curative therapeutics leveraging
CRISPR-based technologies. To fully realize the transformative
potential of CRISPR-based technologies, Intellia is pursuing two
primary approaches. The company’s in vivo programs use
intravenously administered CRISPR as the therapy, in which
proprietary delivery technology enables highly precise editing of
disease-causing genes directly within specific target tissues.
Intellia’s ex vivo programs use CRISPR to create the therapy by
using engineered human cells to treat cancer and autoimmune
diseases. Intellia’s deep scientific, technical and clinical
development experience, along with its robust intellectual property
portfolio, have enabled the company to take a leadership role in
harnessing the full potential of genome editing to create new
classes of genetic medicine. Learn more at intelliatx.com. Follow
us on Twitter @intelliatx.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiSenior Director, Investor Relations and Corporate
Communications +1-857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024